Jipan Xie

Jipan Xie

Auto-generated profile, based on publicly available information

Jipan Xie

XL Source, Inc., Los Angeles, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Medical Economics
Verified
Journal Article
Open access
SJSneha S. Jain
Sneha S. Jain
SLSophia S. Li
Sophia S. Li
JXJipan Xie
Jipan Xie
MSMegan B. Sutton
Megan B. Sutton
JFJennifer T. Fine
Jennifer T. Fine
DCDavid J. Cohen
David J. Cohen
Obstructive hypertrophic cardiomyopathy (oHCM) is a disease of the cardiomyocyte in which dynamic left ventricular outflow track obstruction may lead to heart failure, valvular disease, and sudden...

1 September 2020 in Kidney Medicine
Verified
Journal Article
Open access
BCBorut Cizman
Borut Cizman
HSHelen T. Smith
Helen T. Smith
RCRodrigo Refoios Camejo
Rodrigo Refoios Camejo
LCLinda Casillas
Linda Casillas
HDHarjeet Dhillon
Harjeet Dhillon
DCDaniel Coyne
Daniel Coyne
Since the change in erythropoiesis-stimulating agent (ESA) labeling and bundling of dialysis services in the United States, few studies have addressed the clinical importance of ESA hyporesponsiveness and none have considered health care resource use in this population. We aimed to further explore ESA hyporesponsiveness and its consequences. Retrospective observational cohort study. US Renal Data System Medicare participants receiving dialysis with a minimum 6 months of continuous ESA use from 2012 to 2014. Erythropoietin resistance index (≥2.0 U/kg/wk/g/L) and ESA dose were used to identify ESA hyporesponders and hyporesponsive subgroups: isolated, intermittent, and chronic. Associations between ESA responsiveness and mortality, cardiovascular hospitalization rates, and health care resource use were evaluated and compared across subgroups. Baseline characteristics were compared using Wilcoxon rank sum tests for continuous variables and χ2 tests for categorical variables. Incidence rates of health care resource use were modeled using an unadjusted and adjusted generalized linear model. Of 834,115 dialysis patients in the CROWNWeb database, 38,891 ESA hyporesponders and 59,412 normoresponders met all inclusion criteria. Compared with normoresponders, hyporesponders were younger women, weighed less, and had longer durations of dialysis (all P < 0.001). Hyporesponders received 3.8-fold higher ESA doses (mean, 94,831 U/mo) and erythropoietin resistance index was almost 5 times higher than in normoresponders. Hyporesponders had lower hemoglobin levels and parathyroid hormone levels > 800 pg/mL, and iron deficiency was present in 26.5% versus 10.9% in normoresponders. One-year mortality was higher among hypo- compared with normoresponders (25.3% vs 22.6%). Hyporesponders also had significantly higher rates of hospitalization for cardiovascular events, emergency department visits, inpatient stays, home health agency visits, skilled nursing facility, and hospice days. Only US Medicare patients were included and different hyporesponder definitions may have influenced the results. This study explored ESA hyporesponsiveness using new definitions and incorporated clinical and economic outcomes. It established that ESA-hyporesponsive dialysis patients had higher mortality, cardiovascular hospitalization rates, and health care costs as compared with ESA-normoresponsive patients.

1 June 2021 in Clinical Nutrition ESPEN
Verified
Journal Article
Open access
KCKristina Chen
Kristina Chen
FJFrancisca Joly
Francisca Joly
FMFan Mu
Fan Mu
SKSneha S. Kelkar
Sneha S. Kelkar
COClement Olivier
Clement Olivier
DSDouglas L. Seidner
Douglas L. Seidner
This study aimed to identify predictors and estimate time to teduglutide response among adult patients with short bowel syndrome with intestinal failure (SBS-IF) dependent on parenteral support (PS). Post-hoc analysis was performed on individual patient data from teduglutide-treated patients in the phase III teduglutide trial STEPS and the STEPS-2 extension. Response was defined as ≥20% PS volume reduction from baseline for two consecutive visits. Early responders experienced the reduction at 20 and 24 weeks during STEPS while late responders experienced the reduction during STEPS-2. Timing and predictors for response were assessed among the treated population using Cox proportional hazard model. Time to response was compared in aetiological subgroups using Kaplan-Meier analysis. Patient characteristics and time to response were compared between early vs. late responders. A total of 34 patients were included in this analysis; overall median time to response was 4.3 months. The presence of stoma predicted a positive response to teduglutide (hazard ratio [HR]: 5.6; 95% confidence interval [CI]: 1.4-21.9; p = 0.013). Vascular disease (vs. inflammatory bowel disease [IBD]) as cause of major intestinal resection (HR: 0.2; 95% CI: 0.0-0.8; p = 0.015), presence of ileocecal valve (HR: 0.1; 95% CI: 0.0-0.8; p = 0.047), and female sex (HR: 0.3; 95% CI: 0.1-1.0; p = 0.026) are negatively associated with response. In subgroup analyses, patients with IBD (vs. vascular disease), with (vs. without) a stoma, and without (vs. with) colon-in-continuity had a shorter time to response (all p < 0.05). The mean times to response were 3.6 (standard deviation (SD): 1.1) months for early responders (n = 27) and 10.0 (SD: 6.1) months for late responders (n = 7). Fewer early responders had colon-in-continuity (51.9%) and ileocecal valve (0.0%) compared to late responders (100% and 28.6%, respectively; both p < 0.05). Early responders had a lower mean percentage of colon remaining compared to late responders (24.6% vs. 57.1%, respectively; p = 0.016). Time to response to teduglutide depends on bowel anatomy and SBS-IF aetiology. IBD, presence of a stoma, and absence of ileocecal valve were associated with earlier response to teduglutide. These findings may enhance management of patients with SBS-IF; however, due to sample size limitations, additional studies are needed to confirm these findings.

1 October 2015 in Clinical Breast Cancer
Verified
Journal Article
Closed access
JXJipan Xie
Jipan Xie
YHYanni Hao
Yanni Hao
ZZZheng-Yi Zhou
Zheng-Yi Zhou
CQCynthia Z. Qi
Cynthia Z. Qi
GDGourab De
Gourab De
SGStefan Glück
Stefan Glück

11 May 2023 in Journal of Medical Economics
Verified
Journal Article
Open access
SNSrihari S. Naidu
Srihari S. Naidu
MSMegan B. Sutton
Megan B. Sutton
WGWei Gao
Wei Gao
JFJennifer T. Fine
Jennifer T. Fine
JXJipan Xie
Jipan Xie
AOAnjali Tiku Owens
Anjali Tiku Owens
The diagnostic history in the years leading up to the definitive diagnosis of patients with obstructive hypertrophic cardiomyopathy (HCM) has not been studied.Patients with a delay in the definitiv...

22 December 2021 in Journal of Medical Economics
Verified
Journal Article
Open access
JXJipan Xie
Jipan Xie
YWYan Wang
Yan Wang
YXYaping Xu
Yaping Xu
JFJennifer T. Fine
Jennifer T. Fine
JLJenny Lam
Jenny Lam
LGLouis Garrison
Louis Garrison
To assess the effects of mavacamten on health-related quality-of-life (HRQoL) in symptomatic obstructive hypertrophic cardiomyopathy (HCM) and estimate health utilities by New York Heart Associatio...